RxDoctor Payments Data

Rohan Patel, MD

Clinical Cardiac Electrophysiology · Washington, DCNPI 1932462215

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (50.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Boston Scientific at 38.6% of the total. Reporting peaked in 2019 at $11,075 and has fallen 80.5% since, to $2,159 in 2025.

$19,949in general payments, 2019–2025

Across 300 payments — averaging $66.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$8K
  • Medtronic$8K
  • Abbott$3K
  • Biosense Webster, Inc.$416
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$257
  • Angiodynamics, Inc.$220
  • plus $1K from 13 others

What the payments were for

  • Grants$10,00050%
  • Travel & lodging$1,1156%
  • Food & beverage$8,83444%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$176,424
Medicare patients
1,349
Services billed
2,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban106$94,746
MultaqDronedarone Hcl22$25,169
EntrestoSacubitril/Valsartan18$20,957
XareltoRivaroxaban19$17,617
Dofetilide12$5,406
Metoprolol Succinate76$824
SotalolSotalol Hcl41$635
Amiodarone Hcl15$223
Carvedilol23$167
Digoxin11$65
Amlodipine Besylate12$61
Atorvastatin Calcium12$51

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCMultaq$69$25,16922 claims
Johnson & JohnsonXarelto$33$17,61719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.

Other clinical cardiac electrophysiology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →